

David J R Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11252569/publications.pdf>

Version: 2024-02-01

42
papers

1,495
citations

393982

19
h-index

315357

38
g-index

42
all docs

42
docs citations

42
times ranked

1610
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Resistant Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 720-729.	2.3	5
2	Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 263-276.	1.2	13
3	Pharmacometrics in Australasia—Twenty Years of Population Approach Group of Australia and New Zealand. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 701-704.	1.3	3
4	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1073-1087.	1.1	8
5	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 924-934.	1.1	8
6	Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 201-215.	0.6	9
7	Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties. <i>Current Topics in Medicinal Chemistry</i> , 2019, 18, 2230-2238.	1.0	2
8	Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 181-197.	0.8	5
9	Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. <i>Drugs in R and D</i> , 2017, 17, 189-198.	1.1	7
10	Food, gastrointestinal pH, and models of oral drug absorption. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 234-248.	2.0	197
11	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1046-1057.	1.1	1
12	Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. <i>Pharmaceutical Research</i> , 2016, 33, 1782-1794.	1.7	27
13	A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption—Part I: Gastrointestinal pH. <i>AAPS Journal</i> , 2016, 18, 1309-1321.	2.2	90
14	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 113-123.	1.1	19
15	An introduction to physiologically-based pharmacokinetic models. <i>Paediatric Anaesthesia</i> , 2016, 26, 1036-1046.	0.6	29
16	A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption—Part II: Gastrointestinal Transit Time. <i>AAPS Journal</i> , 2016, 18, 1322-1333.	2.2	58
17	Modelling the PKPD of oxycodone in experimental pain—Impact of opioid receptor polymorphisms. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 86, 41-49.	1.9	3
18	ADVAN-style analytical solutions for common pharmacokinetic models. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 73, 42-48.	0.3	5

#	ARTICLE	IF	CITATIONS
19	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 777-788.	1.1	4
20	Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5681-5696.	1.4	80
21	Pharmacokineticâ€“Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 257-267.	1.2	7
22	A physiologically-based recirculatory meta-model for nasal fentanyl in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 561-576.	0.8	11
23	ABCB1 haplotype and OPRM1 118A & G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 53.	0.4	39
24	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 274-284.	1.2	36
25	Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 360-365.	1.4	14
26	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 895-902.	1.1	23
27	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. <i>Clinical Pharmacokinetics</i> , 2010, 49, 817-827.	1.6	24
28	Pharmacokineticâ€“Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 94-101.	1.2	26
29	Pharmacokineticâ€“Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 619-631.	1.0	54
30	Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1153-1159.	0.8	19
31	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 559-567.	1.0	15
32	Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 326-335.	1.1	15
33	Blood-brain equilibration kinetics of levo- \pm -acetyl-methadol using a chronically instrumented sheep preparation. <i>British Journal of Pharmacology</i> , 2006, 147, 209-217.	2.7	3
34	Cerebral kinetics of oxycodone in conscious sheep. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1666-1676.	1.6	24
35	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 404-413.	1.1	20
36	The Acute Disposition of (R)- and (S)-Methadone in Brain and Lung of Sheep. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 547-570.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 2004, 57, 742-755.	1.1	66
38	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 2004, 58, 536-541.	1.1	17
39	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 2003, 57, 287-297.	1.1	112
40	Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 2000, 50, 427-440.	1.1	110
41	MethadoneN-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 1999, 47, 403-412.	1.1	161
42	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 1999, 65, 685-694.	2.3	119